Filtered By:
Cancer: Acute Leukemia
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 260 results found since Jan 2013.
Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research
Novel nanocarriers for silencing anti-phagocytosis CD47 marker in acute myeloid leukemia cells
Colloids Surf B Biointerfaces. 2022 Jun 1;217:112609. doi: 10.1016/j.colsurfb.2022.112609. Online ahead of print.ABSTRACTAcute myeloid leukemia (AML), a malignant disorder of Hematopoietic stem cells, can escape immunosurveillance by over expression of the cluster of differentiation 47 (CD47) marker, which functions as an inhibitory signal, suppressing phagocytosis by binding to signal regulatory protein α (SIRPα) on macrophages. AML is treated mainly by chemotherapy, which has drastic side effects and poor outcomes for the patients. Most AML patients develop drug resistance, so other methods to treat AML are highly requ...
Source: Colloids and Surfaces - June 6, 2022 Category: Biotechnology Authors: Eman M Hassan Shan Zou Source Type: research
RUNX1 inhibition using lipid nanoparticle-mediated siRNA delivery as an effective treatment for acute leukemias
RUNX1 is one of three mammalian RUNX members, along with RUNX2 and RUNX3. RUNX1 contains a conserved Runt domain that mediates DNA binding and heterodimerization to their partner protein CBFB. RUNX1 and CBFB form a complex that regulates hematopoietic gene expression1-3. Disruption of RUNX1 has been implicated in the development of hematopoietic neoplasms. Chromosomal abnormalities involving the RUNX1 gene are associated with several types of leukemia, including acute myeloid leukemia (AML) driven by RUNX1-RUNX1T14,5.
Source: Experimental Hematology - May 25, 2022 Category: Hematology Authors: Kohei Iida, Akiho Tsuchiya, Moe Tamura, Keita Yamamoto, Shigehisa Kawata, Mitsuko Ishihara-Sugano, Motohiro Kato, Toshio Kitamura, Susumu Goyama Tags: Category: Malignant Hematopoiesis Source Type: research
eEF2K activity determines synergy to co-treatment of cancer cells with PI3K and MEK inhibitors
Mol Cell Proteomics. 2022 May 2:100240. doi: 10.1016/j.mcpro.2022.100240. Online ahead of print.ABSTRACTPI3K-mTOR and MEK/MAPK are the most frequently dysregulated signaling pathways in cancer. A problem that limits the success of therapies that target individual PI3K-MAPK members is that these pathways converge to regulate downstream functions and often compensate each other, leading to drug resistance and transient responses to therapy. In order to overcome resistance, therapies based on co-treatments with PI3K/AKT and MEK/MAPK inhibitors are now being investigated in clinical trials but the mechanisms of sensitivity to ...
Source: Molecular and Cellular Proteomics : MCP - May 5, 2022 Category: Molecular Biology Authors: Maruan Hijazi Pedro Casado Nosheen Akhtar Saul Alvarez-Teijeiro Vinothini Rajeeve Pedro R Cutillas Source Type: research
